ArticleBMC cancer2025
Histological-pathological and clinical T stage of primary adenoid cystic carcinoma of the lacrimal gland in a Chinese population.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo present clinical presentations, histological-pathological patterns, clinical T stage, divergent treating methods, and outcomes of primary adenoid cystic carcinoma (ACC) of the lacrimal gland in a Chinese population.
methodsThis case series included patients with primary lacrimal gland adenoid cystic carcinoma treated at a Chinese hospital between 2003 and 2014. An exploratory multivariate Cox regression analysis was performed to evaluate the prognostic impact of clinical T-stage. Subsequently, Kaplan-Meier survival analysis was conducted, stratifying patients by T-stage (T4 vs. T1-T3) and by surgical approach among T4 patients, to assess the influence of tumor stage and surgical management on disease-free survival outcomes.
resultsA total of 38 patients included 16 men and 22 women with a median age of 46.3 years were enrolled. Sixteen patients (42.11%) had local recurrence, while nineteen patients (50%) had distant metastasis at the time of presentation. Twelve patients (31.58%) were in T1-T3 stage and twenty-six (68.42%) were in T4 stage. Nineteen patients (73.08%) in the T4 stage exhibited a predominantly solid-basaloid pattern, and only three (25%) in T1-T3 stage had a predominantly solid-basaloid pattern histological pattern. Median DFS for the entire cohort was 29.0 months (95% CI, 19.0-39.0), and median survival after metastasis was 7.0 months (95% CI, 3.0-9.0). After adjustment for covariates, T4 stage remained independently associated with significantly shorter DFS (HR = 4.46, 95% CI: 1.40-14.21, P = 0.011). A significant difference in DFS was observed between the T1-T3 and T4 groups (log-rank P = 0.003). Meanwhile, no significant difference in disease-free survival was observed between T4 patients undergoing globe-preserving surgery and eye-sparing approaches (log-rank P = 0.297).
conclusionsIn this Chinese cohort, the solid-basaloid pattern correlated strongly with advanced T4 disease and aggressive behavior. Kaplan-Meier and multivariate Cox analyses consistently demonstrated that T4 stage was independently associated with significantly poorer DFS. For T4 patients, DFS did not differ significantly between exenteration and globe-preserving surgery when combined with radiotherapy, suggesting that eye-sparing approaches may be viable in advanced cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.